Etrolizumab

Report
31 Pages
August 2018
Region: Global
Citeline
ID: 4775309

Drug Overview
Etrolizumab (Roche) is a humanized anti-beta7 integrin subunit monoclonal antibody.

The drug was discovered by Genentech, which was acquired by Roche in 2009. Etrolizumab binds to the beta7 subunit of the alpha4-beta7 and alphaE-beta7 integrin heterodimers. This prevents the interaction of alpha 4-beta7 integrin with mucosal addressing cell adhesion molecule-1 and the interaction of alphaE-beta7 integrin with E-cadherin.

In turn, this results in interference with immune cell trafficking into the intestine in a selective manner that avoids broad immunosuppression.

The drug is in late-phase development in Crohn’s disease and ulcerative colitis. The US Food and Drug Administration has granted orphan drug designation to Etrolizumab for pediatric patients.

OVERVIEW

Drug Overview
Product Profiles
etrolizumab: Crohn's disease
etrolizumab: Ulcerative colitis

LIST OF FIGURES

Figure 1: Etrolizumab for Crohn’s disease – SWOT analysis
Figure 2: The authors drug assessment summary of etrolizumab in Crohn’s disease
Figure 3: The authors drug assessment summary of etrolizumab in Crohn’s disease
Figure 4: Etrolizumab sales for Crohn’s disease across the US and five major EU markets, by country, 2016–25
Figure 5: Etrolizumab for ulcerative colitis – SWOT analysis
Figure 6: The authors drug assessment summary of etrolizumab for ulcerative colitis
Figure 7: The authors drug assessment summary of etrolizumab for ulcerative colitis

LIST OF TABLES

Table 1: Etrolizumab drug profile
Table 2: Ongoing pivotal trials for etrolizumab in Crohn’s disease
Table 3: Other late-phase trials for etrolizumab in Crohn’s disease
Table 4: Etrolizumab sales for Crohn’s disease across the US and five major EU markets, by country, 2016–25
Table 5: Etrolizumab drug profile
Table 6: Etrolizumab Phase III trials in ulcerative colitis
Table 7: Etrolizumab ongoing Phase III trials in ulcerative colitis

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€9630EUR$10,000USD£8,282GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€47187EUR$49,000USD£40,583GBP

Table of Contents

Related Topics

Related Reports

Ulcerative Colitis (UC) - Market Insight, Epidemiology And Market Forecast - 2032

Inflammatory Bowel Disease (IBD) Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

Ulcerative Colitis - Pipeline Insight, 2024

Inflammatory Bowel Diseases (IBD) Drugs Market Report 2024-2034

Gastrointestinal Therapeutics - Global Strategic Business Report